Current treatment modalities for primary central nervous system (CNS) and leptomeningeal (LPM) malignancies have proven inadequate. Eradication of LPM disease may be enhanced by direct compartmental therapy of tumor-specific agents maximizing concentration to tumor sites while reducing systemic toxicities. To test this principle, we employed the intrathecal (IT) radiolableled murine monoclonal antibody 3F8 targeting tumor associated GD2 in healthy non-human primates, whose GD2 tissue distribution (DNS and peripheral) is identical to that in humans. We demonstrated that IT 131I-3F8 can deliver a high dose of radiation (up to 82 Gy) to the CSF, with tolerable side effects. Moreover, serum antibody against the MoAb was 1422 fold higher than that in the SF, thereby accelerating blood clearance (reducing blood radiation dose) without affecting CSF pharmacokinetics. We now propose to define the role of compartment radioimmunotherapy by assessing the pharmacokinetics and dosimetry of IT131 I-3F8 in relation to HAMA production, clinical efficacy and toxicity in a phase I dose-escalation (10 to 50 mCi) clinical trial for patients with GD2-expressing CNS malignancies. We further propose to manipulate drug delivery in the thecal space of non-human primates to maximize the CSF:blood ratio. Using genetically engineered anti- GD2 single chain and signs chain-streptavidin constructs differing in both size and binding characteristics, these novel IT agents will be tested in cynomolgus monkeys, the results of which are applicable to human patients. These measurements are critical for the optimization of antibody constructs and other targeted agents that may contribute to more effective treatment modalities for patients with CNS malignancies and related disorders.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Cheung, Nai-Kong V; Cheung, Irene Y; Kramer, Kim et al. (2014) Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 135:2199-205
Cheung, Nai-Kong V; Cheung, Irene Y; Kushner, Brian H et al. (2012) Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 30:3264-70
Kushner, Brian H; Kramer, Kim; Modak, Shakeel et al. (2010) Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer 116:3054-60
Modak, Shakeel; Cheung, Nai-Kong V (2010) Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 36:307-17
Kushner, Brian H; Cheung, Nai-Kong V; Barker, Christopher A et al. (2009) Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 75:1181-6
Kushner, Brian H; Kramer, Kim; Modak, Shakeel et al. (2009) Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 27:1041-6
Modak, Shakeel; Kushner, Brian H; LaQuaglia, Michael P et al. (2009) Management and outcome of stage 3 neuroblastoma. Eur J Cancer 45:90-8
Kramer, Kim; Humm, John L; Souweidane, Mark M et al. (2007) Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25:5465-70
Kushner, Brian H; Cheung, Irene Y; Kramer, Kim et al. (2007) High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer 48:430-4
Kushner, Brian H; Kramer, Kim; Modak, Shakeel et al. (2006) Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol 24:5271-6

Showing the most recent 10 out of 31 publications